|
|
Article: Study findings from E.A. Macgregor et al provide new insights into adverse drug reactions.
- Article from:
- Women's Health Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
According to a study from London, the United Kingdom, "Objective.- To assess the safety and tolerability profile of the 5-HT1B/1D agonist frovatriptan (Frova [R], Endo Pharmaceuticals Inc., Chadds Ford, PA, USA) when used as a 6-day regimen for the short-term prevention of menstrual migraine scheduled over multiple perimenstrual periods. Background.- Two randomized controlled trials have established the efficacy of a 6-day regimen of frovatriptan for reducing the incidence and severity of menstrual migraine over 1 to 3 perimenstrual periods; long-term data are needed to further assess the safety and tolerability profile of this regimen."
"Methods.- Two ...